K
Keros Therapeutics, Inc. (KROS)
NGM – Real Time Price. Currency in USD
11.20
+0.56 (5.26%)
At close: Aug 12, 2026, 4:00 PM EDT
11.20
0.00 (0.00%)
After-hours: Aug 12, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
11.20
+0.56 (5.26%)
At close: Aug 12, 2026, 4:00 PM EDT
11.20
0.00 (0.00%)
After-hours: Aug 12, 2026, 4:10 PM EDT
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
| Name | Position |
|---|---|
| Dr. Jasbir S. Seehra Ph.D. | President, CEO & Director |
| Dr. Lorena Lerner Ph.D. | Chief Scientific Officer |
| Justin Frantz | Head of Investor Relations |
| Ms. Annita Tanini | VP, Corporate Controller and Interim Principal Financial & Accounting Officer |
| Ms. Esther Cho J.D. | Chief Legal Officer & Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-08-03 | 8-K | kros-20260803.htm |
| 2026-07-30 | 8-K | kros-20260730.htm |
| 2026-07-22 | 8-K | kros-20260717.htm |
| 2026-06-25 | 8-K | kros-20260623.htm |
| 2026-06-03 | 8-K | kros-20260603.htm |
| 2026-06-01 | 8-K | kros-20260601.htm |
| 2026-05-14 | 8-K | kros-20260514.htm |
| 2026-05-14 | 10-Q | kros-20260331.htm |
| 2026-04-22 | DEFA14A | tm261345d3_defa14a.htm |
| 2026-04-22 | DEF 14A | tm261345-1_def14a.htm |